Eucalyn, a green, oil from the genus Eucaryoticus, is a great source of omega-3 fatty acids, a powerful anti-inflammatory and a good source of vitamins A and E. Eucalsyn is also known as Eucamid, and it contains a variety of other beneficial compounds, including eucaloric acid.
But now a team of researchers has found that this green oil can also reduce inflammation in humans.
EUCALYPTUS OIL CAN CAUSE CAUSES COLLICUT DISEASE In a recent study, a team from the Department of Nutritional Sciences at the University of California, Davis, analyzed the relationship between eucalypsin oil and the inflammatory response in people with type 2 diabetes.
The researchers used a modified version of the Food and Drug Administration’s (FDA) Food Drug Safety Dose-Induced Inflammatory Response (FDSIR) test, which measures the inflammatory changes caused by foods, to assess the effectiveness of eucalsys oil.
The test is commonly used in studies to identify the most likely trigger for food allergies, but researchers used it to identify possible mechanisms that could contribute to type 2 diabetics’ inflammation.
They found that the test’s sensitivity and specificity improved as the oil was applied to the skin of diabetic patients.
However, the test did not work well on patients who had underlying medical conditions, including diabetes.
“In other words, there are still a lot of unknowns with this study, but we have a promising avenue to explore that could lead to a more accurate assessment of the impact of oil on insulin sensitivity,” said lead author and postdoctoral fellow Michael B. Wojciechowski.
He said the findings are an important first step toward understanding the relationship of eumels on the body’s immune system to the inflammatory process in type 2 diabetic patients and their inflammatory response.
“These results suggest that eucallysyl oil can reduce the inflammation that we see in people diagnosed with type two diabetes and that eumel-based oil can actually decrease the inflammation associated with the inflammatory processes,” Wojchowski said.
In the study, the researchers used an oil mixture of euccalyptol, an olive oil derivative, and eucasyn, an oil derivative from the Eucales genus.
The study was published online in the journal Nutrients.
The results showed that the EUCALSYL compound significantly reduced the inflammation caused by the test, as measured by the FDSIR.
When the researchers applied the mixture to the subjects’ skin and compared it with that of control subjects, they found that there was a significant reduction in the skin inflammation in both groups.
The FDSir was also reduced by eucalesyn.
The team also used a non-steroidal anti-inflammatory drug (NSAID) on the subjects to lower the inflammation.
The oil reduced inflammation by roughly 25% in subjects treated with NSAIDs compared to placebo.
“We believe that euccalysyn-based oils are likely to have some therapeutic effects in the future for people with diabetes,” Wozciechanowski said, noting that this oil is already widely used in the healthcare system and is widely used by diabetologists in other parts of the world.
“This study indicates that we should consider using the FADSIR as a more sensitive biomarker of inflammation and that these oils could potentially be helpful in developing and targeting therapeutic approaches to improve the inflammatory and metabolic response in type two diabetic patients.”
Eucalisyn oil was also shown to reduce insulin sensitivity in diabetic mice.
The scientists tested the effect of the oil on the animals’ ability to generate insulin in response to glucose.
They also tested the effects of the olive oil on glucose tolerance in a control group of mice.
“When we compared these two groups, we found that both olive oil and euccalisyn significantly increased glucose tolerance, as evidenced by a decrease in the insulin sensitivity compared to the control group,” Woschowski added.
The investigators concluded that eustalypse oil is an effective treatment for type 2 and type 3 diabetes, and may provide a new strategy for treating type 2.
The next step is to determine whether this oil also reduces inflammation in type 1 diabetias.
The research was supported by grants from the National Institutes of Health and the National Heart, Lung and Blood Institute.